TWYNEO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TWYNEO (TWYNEO).
TWYNEO is a fixed-dose combination of tretinoin (retinoic acid receptor agonist) and benzoyl peroxide (antimicrobial and keratolytic). Tretinoin normalizes follicular keratinization and reduces comedone formation. Benzoyl peroxide has bactericidal activity against Propionibacterium acnes and produces mild exfoliation.
| Metabolism | Tretinoin is metabolized in the liver via oxidation by CYP2A6, CYP2B6, and CYP2E1 to metabolites including 4-hydroxy-, 4-oxo-, and 18-hydroxy-tretinoin. Benzoyl peroxide is degraded to benzoic acid, which undergoes conjugation with glycine to form hippuric acid and is excreted renally. |
| Excretion | Primarily hepatic metabolism; metabolites excreted renally (approx. 60%) and fecally (approx. 30%). |
| Half-life | Terminal half-life of tretinoin: 1-2 hours; benzoyl peroxide: <1 hour; clinical context: tretinoin undergoes rapid metabolism, benzoyl peroxide is degraded rapidly. |
| Protein binding | Tretinoin: >95% bound primarily to albumin; benzoyl peroxide: negligible binding. |
| Volume of Distribution | Tretinoin: not well-characterized topically, estimated 0.3-0.5 L/kg; benzoyl peroxide: limited systemic absorption. |
| Bioavailability | Topical: minimal systemic absorption (<2% for tretinoin; benzoyl peroxide is degraded in skin). |
| Onset of Action | Topical: noticeable reduction in acne lesions within 2-4 weeks of daily application. |
| Duration of Action | Sustained with continued use; effects persist as long as therapy is maintained; clinical improvement plateaus by 12 weeks. |
| Molecular Weight | 300.44 Da (tretinoin); 242.23 Da (benzoyl peroxide) |
Twice daily topical application of a pea-sized amount to affected areas of the face and trunk.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; insufficient data for severe impairment. |
| Liver impairment | No specific guidelines for hepatic impairment; use caution in severe impairment. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific adjustment; use caution due to potential increased skin sensitivity. |
| 1st trimester | Tretinoin is contraindicated in pregnancy due to teratogenicity (retinoid embryopathy). Benzoyl peroxide has limited data but is generally avoided in first trimester unless clearly needed. |
| 2nd trimester | Contraindicated: tretinoin is a retinoid with known teratogenic effects. Avoid use. |
| 3rd trimester | Contraindicated: tretinoin. Use alternative therapies, especially near term due to potential for systemic absorption. |
Clinical note
Comprehensive clinical and safety monograph for TWYNEO (TWYNEO).
| Placental transfer | Tretinoin is known to cross the placenta and has been associated with retinoid embryopathy. Benzoyl peroxide is rapidly metabolized to benzoic acid, which crosses placenta but is generally considered low risk in limited doses. |
| Breastfeeding | Tretinoin is excreted in breast milk in low amounts; however, due to potential adverse effects on the infant (e.g., retinoid toxicity), avoidance is recommended. Benzoyl peroxide is poorly absorbed and considered compatible, but combination product risk outweighs benefit. Use alternative therapy. |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyHypersensitivity to tretinoin, benzoyl peroxide, or any component of the formulation
| Precautions | Photosensitivity and use of sun protection, Local cutaneous reactions including erythema, scaling, dryness, burning, and stinging, Avoid excessive exposure to sunlight and UV light, Concomitant use of topical products with skin drying or exfoliating effects, Use in pregnancy only if clearly needed (Tretinoin is teratogenic in animals) |
| Food/Dietary | No clinically significant food interactions have been reported. However, limit consumption of oily foods if they exacerbate acne. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | TWYNEO (tretinoin 0.1% cream with benzoyl peroxide 3% cream) is contraindicated in pregnancy. Based on the retinoid component (tretinoin), there is a known teratogenic risk in the first trimester (major congenital malformations). Topical absorption is minimal, but systemic exposure cannot be ruled out. Avoid use in pregnancy. |
| Fetal Monitoring | No specific fetal monitoring required as this is topical. Inadvertent use during pregnancy should prompt pregnancy testing and ultrasound to evaluate for fetal anomalies. |
| Fertility Effects | No known effects on fertility. |
| Clinical Pearls |
| Twynéo (tretinoin 0.1% and benzoyl peroxide 3% cream) is a fixed-dose combination for acne vulgaris. Avoid simultaneous application with other topical products containing benzoyl peroxide or retinoids to prevent excessive irritation. Apply a pea-sized amount to entire face after cleansing and drying. Use sunscreen daily and avoid prolonged sun exposure because of photosensitization. Initiate with every-other-day application to improve tolerability, then titrate to daily use as tolerated. Do not use in patients with known allergy to benzoyl peroxide or retinoids. Pregnancy risk category C (tretinoin); use only if clearly needed. |
| Patient Advice | Apply only a pea-sized amount to the entire face once daily at night after washing and drying the skin. · Do not apply to broken, eczematous, or sunburned skin. · You may experience redness, peeling, dryness, or stinging initially; this usually improves with continued use. · Use a gentle cleanser and oil-free moisturizer to reduce irritation. · Avoid other topical acne products (including benzoyl peroxide or retinoids) unless directed by your clinician. · Use sunscreen with SPF 30 or higher every day and avoid tanning beds and excessive sun exposure. · Pregnancy warning: If you become pregnant or plan to become pregnant, contact your clinician as tretinoin may be harmful to the fetus. · Do not use more than prescribed; overuse increases irritation without additional benefit. |